Link's New Modifier for Improved Oligo Delivery
Link Technologies Ltd, an ISO 9001:2008 certified specialist oligonucleotide reagent manufacturer, has expanded its range of lipophilic modifiers for the effective delivery of oligonucleotides into cells.
As oligos continue to be of interest in drug discovery, offering exciting potential as therapeutic agents, there is an increasing demand for improved oligo delivery techniques. Link’s proven collection of lipophilic oligo modification reagents, which include cholesterol and tocopherol modifiers, now also includes 5’-Palmitate-C6-CE Phosphoramidite. As a derivative of palmitic acid, a physiologically common fatty acid, the new palmitate modifier is the first palmitate phosphoramidite available commercially, and provides scientists with an ideal approach to improve the cellular uptake and utilisation of oligos.
In the cell, palmitic acid is known to conjugate to proteins via cysteine residues and, in doing so, is believed to aid the movement of proteins between intracellular compartments. It is also known that improved cell delivery is achieved when an oligonucleotide is modified with palmitic acid, and that modification at the 5’-end results in more efficient uptake than modification at the 3’-end. However, until now, modification of the 5’-end of the oligo with palmitic acid has proved inefficient. For this reason, Link has developed 5’-Palmitate-C6-CE Phosphoramidite, the first of its palmitic acid derived phosphoramidites, as a dedicated delivery reagent. When incorporated during oligo synthesis, the use of this novel palmitate modifier can result in more efficient uptake of the oligonucleotide by the cell, offering important value particularly for therapeutic applications.
Commenting on the new addition to Link’s breakthrough range of lipophilic modifiers, Catherine McKeen, Head of Technology Commercialisation, explained: “Labelling oligos with hydrophobic compounds has proved a successful technique for enhancing cell delivery. We are continuing to develop our range of reagents for use in this field so that we can always offer our customers the most effective methods for oligo delivery. Palmitate, due to its proven ability to improve oligonucleotide delivery, is a natural choice for addition to our delivery agent portfolio.”
Available from small milligramme quantities to larger bulk scale, 5’-Palmitate-C6-CE Phosphoramidite can be ordered online from the Link website. Scientists can also access protocol information online, detailing the use of 5’-Palmitate in oligonucleotide synthesis, for confident incorporation and application of this lipophilic modifier.
www.linktech.co.uk
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance